Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro.

Antiviral research - 1 Aug 2017

Berke Jan Martin, Tan Ying, Verbinnen Thierry, Dehertogh Pascale, Vergauwen Karen, Vos Ann, Lenz Oliver, Pauwels Frederik

Abstract excerpt

The HBV core protein represents an attractive target for new antiviral therapies due to its multiple functions within the viral life-cycle. Here, we report the antiviral activity of the capsid assembly modulator (CAM) BAY41-4109 and two nucleos(t)ide analogues (NAs) on a diverse panel of 54 HBV clinical isolates from genotype (GT) A-H and assessed the impact of core amino acid (aa) substitutions using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Hepatitis B Core Antigens

Share to Hepatitis B virus

Share to Microbial Sensitivity Tests

Share to Mutation, Missense

Share to Virus Assembly

Source

Identifiers

PMID: 28647474
DOI: 10.1016/j.antiviral.2017.06.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro.PMID 28647474Read ↗

Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro.Semantic proximity Read ↗

Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus.Semantic proximity Read ↗

Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profilesSemantic proximity Read ↗

The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral TargetSemantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.Semantic proximity Read ↗

Assembly Properties of Hepatitis B Virus Core Protein Mutants Correlate with Their Resistance to Assembly-Directed Antivirals.Semantic proximity Read ↗

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731Semantic proximity Read ↗

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity Read ↗

A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsidSemantic proximity Read ↗

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis BSemantic proximity Read ↗

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.